LANSOPRAZOLE ORODISPERSIBLE TABLETS PDF

Patient information for LANSOPRAZOLE 30MG ORODISPERSIBLE TABLETS Including dosage instructions and possible side effects. orodispersible tablets lansoprazole. Read all of this leaflet carefully before you start taking this medicine because it contains important. To view details for LANSOPRAZOLE 30MG ORODISPERSIBLE TABLETS, please read and accept the disclaimer or go back to product listing for.

Author: Zuk Kagakree
Country: Bulgaria
Language: English (Spanish)
Genre: Spiritual
Published (Last): 17 March 2009
Pages: 123
PDF File Size: 13.68 Mb
ePub File Size: 15.73 Mb
ISBN: 395-5-20081-210-3
Downloads: 93138
Price: Free* [*Free Regsitration Required]
Uploader: Daizahn

Each orodispersible tablet contains 30 mg of lansoprazole Excipient s with known effect: Available for Android and iOS devices.

LANSOPRAZOLE 30MG ORODISPERSIBLE TABLETS |

Six months after successful eradication treatment, the risk of re infection is low and relapse tabletw therefore unlikely. There is no evidence of accumulation following multiple doses in healthy subjects.

This includes any possible side effects not listed in this leaflet. Place the tablet on your tongue and suck gently.

Lansoprazole 30mg Orodispersible Tablets

What you need to know before you take Lansoprazole 30 mg Orodispersible Tablets 3. In orodiispersible not fully healed within this time, the medication is continued at the same dose for another two weeks. Use in children and adolescents Lansoprazole 30 mg Orodispersible Tablets should not be given to children. Treatment of duodenal ulcer: Lansoprazole 30mg orodispersible tablets are available in packs of 7, 14, orodisperaible, 56 and 98 tablets.

Never give it to other people even if their condition appears to be the same as yours. To give your medicine the best chance of working, take it at the right time and do not miss a dose.

  MALCADOR DEFENDER PDF

Arthralgia, myalgia Fracture of the hip, wrist or spine see section 4. Studies have shown that oro-dispersible tablets dispersed in a small amount of water and given via syringe directly into the mouth or administered via naso-gastric tube result in equivalent AUC compared to the usual mode of administration.

ododispersible

In patients suffering from gastro-duodenal ulcers, the possibility of H. What is in this leaflet 1. Adverse drug reactions such as dizziness, vertigovisual disturbances and somnolence may occur see section 4. Some lansoprazolee this increase may be due to other risk factors.

How to take Lansoprazole 30 mg Orodispersible Tablets Always take this medicine exactly as your doctor or pharmacist has told you.

Lansoprazole 30mg Orodispersible Tablets – Summary of Product Characteristics (SmPC) – (eMC)

Interference with laboratory tests Increased Chromogranin A CgA level may interfere with investigations for neuroendocrine tumours. Hypomagnesaemia see section 4. Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeated dose toxicity, toxicity to reproduction or genotoxicity.

Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. A rapid relief of symptoms is obtained by one oro-dispersible tablet 30 mg daily, and most patients with duodenal ulcer recover within 2 weeks, patients with gastric ulcer and lansopraaole oesophagitis within 4 weeks.

  ATYS 6E PDF

Lansoprazole orodispersible tablets are strawberry flavoured and should be placed on the tongue and gently sucked. During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion.

The treatment for the prevention of peptic ulceration of patients in need of continuous NSAID treatment should be restricted to high risk patients e. Higher exposure to lansoprazole in comparison to adults has been seen in infants below the age of months with doses of both 1.

Gastric ulcer; duodenal ulcer; gastro-oesophageal reflux disease; Helicobacter pylori infection; Zollinger-Ellison syndrome; acid-related dyspepsia. Pharmacokinetics in paediatric patients The evaluation of the pharmacokinetics in children aged 1 —17 years of age showed a similar exposure as compared to adults with doses of 15 mg for those below 30 kg of weight and 30 mg for those above. This article is for information only and should not be used for the diagnosis or treatment of medical conditions.

Daily doses of up to mg have been used. Why not subscribe to the newsletter? Sulphone, sulphide and 5-hydroxyl derivatives of lansoprazole have been identified in plasma. By continuing to browse the site you are agreeing to our policy on the use of cookies.